X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with J.B.Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs J.B.CHEMICALS - Comparison Results

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA J.B.CHEMICALS NATCO PHARMA/
J.B.CHEMICALS
 
P/E (TTM) x 23.6 15.1 156.1% View Chart
P/BV x 17.9 2.4 748.0% View Chart
Dividend Yield % 0.6 0.2 394.7%  

Financials

 NATCO PHARMA   J.B.CHEMICALS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
J.B.CHEMICALS
Mar-16
NATCO PHARMA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs877318 275.7%   
Low Rs424200 212.3%   
Sales per share (Unadj.) Rs223.4148.0 151.0%  
Earnings per share (Unadj.) Rs31.119.1 162.8%  
Cash flow per share (Unadj.) Rs40.323.9 168.2%  
Dividends per share (Unadj.) Rs5.000.50 1,000.0%  
Dividend yield (eoy) %0.80.2 398.0%  
Book value per share (Unadj.) Rs219.5128.9 170.2%  
Shares outstanding (eoy) m33.0784.82 39.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.91.7 166.4%   
Avg P/E ratio x20.913.6 154.3%  
P/CF ratio (eoy) x16.110.8 149.4%  
Price / Book Value ratio x3.02.0 147.6%  
Dividend payout %16.12.6 614.3%   
Avg Mkt Cap Rs m21,50421,951 98.0%   
No. of employees `000NA2.7 0.0%   
Total wages/salary Rs m1,1281,841 61.2%   
Avg. sales/employee Rs ThNM4,590.9-  
Avg. wages/employee Rs ThNM673.4-  
Avg. net profit/employee Rs ThNM592.1-  
INCOME DATA
Net Sales Rs m7,38912,551 58.9%  
Other income Rs m167542 30.9%   
Total revenues Rs m7,55613,093 57.7%   
Gross profit Rs m1,7932,055 87.3%  
Depreciation Rs m304412 73.8%   
Interest Rs m36696 382.7%   
Profit before tax Rs m1,2902,088 61.8%   
Minority Interest Rs m460 -11,575.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309469 65.8%   
Profit after tax Rs m1,0271,619 63.5%  
Gross profit margin %24.316.4 148.3%  
Effective tax rate %23.922.5 106.5%   
Net profit margin %13.912.9 107.8%  
BALANCE SHEET DATA
Current assets Rs m3,6817,778 47.3%   
Current liabilities Rs m3,1234,358 71.7%   
Net working cap to sales %7.627.2 27.7%  
Current ratio x1.21.8 66.1%  
Inventory Days Days8955 163.7%  
Debtors Days Days5980 73.3%  
Net fixed assets Rs m7,6855,713 134.5%   
Share capital Rs m331170 195.0%   
"Free" reserves Rs m6,67010,547 63.2%   
Net worth Rs m7,25910,937 66.4%   
Long term debt Rs m9550-   
Total assets Rs m11,95715,574 76.8%  
Interest coverage x4.522.8 19.8%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.8 76.7%   
Return on assets %11.711.0 105.9%  
Return on equity %14.214.8 95.6%  
Return on capital %20.720.0 103.8%  
Exports to sales %39.448.7 80.8%   
Imports to sales %5.77.1 80.5%   
Exports (fob) Rs m2,9086,115 47.6%   
Imports (cif) Rs m421889 47.4%   
Fx inflow Rs m3,4456,169 55.9%   
Fx outflow Rs m7031,285 54.7%   
Net fx Rs m2,7434,884 56.2%   
CASH FLOW
From Operations Rs m1,4401,397 103.1%  
From Investments Rs m-1,089-320 340.1%  
From Financial Activity Rs m-353-1,196 29.5%  
Net Cashflow Rs m-1-102 1.5%  

Share Holding

Indian Promoters % 52.0 55.4 93.9%  
Foreign collaborators % 1.5 0.3 490.0%  
Indian inst/Mut Fund % 7.8 3.4 231.3%  
FIIs % 16.6 3.9 426.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 37.0 70.3%  
Shareholders   25,395 30,437 83.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  VENUS REMEDIES  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Blueprint for Sensex 100,000(The 5 Minute Wrapup)

Feb 20, 2018

Investing in stocks is not about index gazing. There are 3-Ms that could help pick the right stocks.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 26, 2018 09:33 AM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS